SCHEMBL9922425

SCHEMBL9922425

Cc1ccc(S(=O)(=O)NC(=O)Nc2ccc(N3C(=O)Cc4cc5c(cc4C3=O)CCN5)cc2)s1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.37
CREBBP Q92793 1/20 0.37
P2RY12 Q9H244 1/20 0.35
GAA P10253 3/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
KCNA1 Q09470 4/20 0.33
KCNAB1 Q14722 4/20 0.33
NLRP3 Q96P20 4/20 0.32
TLR9 Q9NR96 1/20 0.31
HDAC3 O15379 1/20 0.31
HDAC4 P56524 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC7 Q8WUI4 1/20 0.31
HDAC2 Q92769 1/20 0.31
HDAC10 Q969S8 1/20 0.31
HDAC11 Q96DB2 1/20 0.31
HDAC8 Q9BY41 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12160790 0.90 P2RY12 (0.43) P2RY12MEN1KMT2ASMN1; SMN2KCNA1
SCHEMBL9922839 0.88 P2RY12 (0.35) P2RY12GAAMEN1KMT2ASMN1; SMN2
SCHEMBL12161524 0.86 PTGER3 (0.37) P2RY12KCNA1KCNAB1
SCHEMBL14113565 0.85 GAA (0.38) BRD4CREBBPP2RY12GAAMEN1
SCHEMBL9922444 0.84 BRD4 (0.34) BRD4CREBBPP2RY12MEN1KMT2A
SCHEMBL13638361 0.83 KMT2A (0.50) BRD4CREBBPGAAMEN1KMT2A
SCHEMBL13638362 0.82 P2RY12 (0.40) BRD4CREBBPP2RY12GAAMEN1
SCHEMBL13638364 0.82 P2RY12 (0.40) BRD4CREBBPP2RY12GAAMEN1
SCHEMBL9922482 0.81 P2RY12 (0.39) P2RY12MEN1KMT2ASMN1; SMN2KCNA1
SCHEMBL12177620 0.80 BRD4 (0.37) BRD4CREBBPP2RY12GAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS TBXA2R, GP6, P2RY6 BRD4 3064/4885CREBBP 3041/4885P2RY12 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.